Natixis’s Bright Minds Biosciences DRUG Stock Holding History

Natixis’s Portfolio DRUG Stock Details DRUG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$89.2K	Buy	+1,791	New	+$126K	﹤0.01%	969

Other funds holding DRUG

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $796M AUM 17.24% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13B AUM 35.88% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Natixis's DRUG Position: Q3 2026 in Review

Natixis opened a new position in Bright Minds Biosciences (DRUG) in Q3 2026: 1,791 shares worth $89.2K. The stake represents ﹤0.01% of the portfolio and ranks #969 among its holdings.

30 funds tracked by Wall St. Rank hold DRUG as of Q3 2026.

Natixis held 1,791 shares of Bright Minds Biosciences worth $89.2K as of Q3 2026.
Bright Minds Biosciences was a new Natixis position in Q3 2026.
Bright Minds Biosciences made up ﹤0.01% of Natixis's portfolio in Q3 2026, its #969 holding.
30 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q3 2026.

Based on Natixis's 13F filing for Q3 2026, filed 6 Nov 2026.